The CEO Wrote a Million After the Board Already Bought

ISB Research · Favorable · sent to Ultimate members September 28, 2026

This is the second insider check on Inhibrx today, and now the top of the house steps in. Mark Lappe put nearly $999,000 into this clinical-stage biotech chasing therapies for chondrosarcoma and other life-threatening cancers, and he's been buying all year, nine purchases and running. The stock sits near the bottom third of its yearly range with the broad market still holding up, which is the kind of location that's worked for insider buys before. The catch is the tape itself. Short-term trend still says sell while the medium and long frames have turned up, so a trader who agrees with Lappe could sell a put spread under his $99.88 price and get paid to wait for those timeframes to line up.

Ultimate members received this analysis in real time.